论文部分内容阅读
Selegiline(L-deprenyl)是一种选择性单胺氧化酶-B(MAO-B)抑制剂,与左旋多巴伍用已成功地治疗帕金森病。可减少左旋多巴剂量,稳定的延长其作用时间。延长病程及寿命。Selegiline能在帕金森病患者多巴胺(DA)的合成和代谢方面起重要作用。此外,在未用左旋多巴治疗的病人中,Selegiline可抑制DA脱氨基作用和增强DA的有效性。本文包括20例特发性帕金森病患者,年龄43～70岁,平均57.9岁;平均病程4.1年;所有患者均未用过左旋多巴治疗。全部病人均口服安慰剂和盐酸Selegiline。采用临床随机双盲对照法,Selegiline治疗8周,用安慰剂治疗4周。Selegiline开始用量为5mg/日,每周增加5mg/日,6周内增至最大量30mg/日,
Selegiline (L-deprenyl) is a selective monoamine oxidase-B (MAO-B) inhibitor that has been successfully used to treat Parkinson’s disease in combination with levodopa. Can reduce the dose of levodopa, and prolong its duration of action. Prolong course and longevity. Selegiline plays an important role in the synthesis and metabolism of dopamine (DA) in Parkinson’s disease. In addition, Selegiline inhibits DA deamination and enhances the effectiveness of DA in patients not treated with levodopa. This article includes 20 patients with idiopathic Parkinson’s disease, aged 43 to 70 years, mean 57.9 years; average duration of 4.1 years; all patients had not been treated with levodopa. All patients were given oral placebo and Selegiline hydrochloride. Selegiline was treated for 8 weeks in a randomized, double-blind, controlled clinical trial and placebo for 4 weeks. Selegiline starting dose of 5mg / day, weekly increase of 5mg / day, 6 weeks to the maximum amount of 30mg / day,